Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
Martin JE, Khalife-Hachem S, Grinda T, Kfoury M, Garciaz S, Pasquier F, Vargaftig J, Uzunov M, Belhabri A, Bertoli S, Cotteret S, Vergé V, Renneville A, Rosselli F, Antony-Debre I, Rouleau E, Salviat F, Caron O, Delaloge S, Pautier P, Etienne G, Recher C, Vey N, De Botton S, Leary A, Marzac C, Micol JB. Martin JE, et al. Among authors: garciaz s. Ann Oncol. 2021 Aug;32(8):1046-1048. doi: 10.1016/j.annonc.2021.04.015. Epub 2021 Jun 6. Ann Oncol. 2021. PMID: 34107346 Free article. No abstract available.
Epigenetic down-regulation of the HIST1 locus predicts better prognosis in acute myeloid leukemia with NPM1 mutation.
Garciaz S, N'guyen Dasi L, Finetti P, Chevalier C, Vernerey J, Poplineau M, Platet N, Audebert S, Pophillat M, Camoin L, Bertucci F, Calmels B, Récher C, Birnbaum D, Chabannon C, Vey N, Duprez E. Garciaz S, et al. Clin Epigenetics. 2019 Oct 12;11(1):141. doi: 10.1186/s13148-019-0738-6. Clin Epigenetics. 2019. PMID: 31606046 Free PMC article.
Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience.
Marmouset V, Decroocq J, Garciaz S, Etienne G, Belhabri A, Bertoli S, Gastaud L, Simand C, Chantepie S, Uzunov M, Genthon A, Berthon C, Chiche E, Dumas PY, Vargaftig J, Salmeron G, Lemasle E, Tavernier E, Delage J, Loirat M, Morineau N, Blanc-Durand F, Pautier P, Vergé V, Auger N, Thomas M, Stefani L, Lepelley M, Boyer T, Thepot S, Gourin MP, Bourquard P, Duchmann M, Morice PM, Michallet M, Adès L, Fenaux P, Récher C, Dombret H, Pagès A, Marzac C, Leary A, Micol JB; UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM. Marmouset V, et al. Among authors: garciaz s. Clin Cancer Res. 2022 Dec 1;28(23):5211-5220. doi: 10.1158/1078-0432.CCR-22-1622. Clin Cancer Res. 2022. PMID: 36201165
[Myelodysplastic syndromes].
Garciaz S, Vey N. Garciaz S, et al. Rev Prat. 2023 Feb;73(2):221-226. Rev Prat. 2023. PMID: 36916268 French. No abstract available.
Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
Petit C, Saillard C, Mohty B, Hicheri Y, Villetard F, Maisano V, Charbonnier A, Rey J, D'Incan E, Rouzaud C, Gelsi-Boyer V, Murati A, Lhoumeau AC, Ittel A, Mozziconacci MJ, Alary AS, Hospital MA, Vey N, Garciaz S. Petit C, et al. Among authors: garciaz s. Eur J Haematol. 2024 Apr;112(4):530-537. doi: 10.1111/ejh.14140. Epub 2023 Nov 29. Eur J Haematol. 2024. PMID: 38031389
Erythroleukemia: Classification.
Cervera N, Guille A, Adélaïde J, Hospital MA, Garciaz S, Mozziconacci MJ, Vey N, Gelsi-Boyer V, Birnbaum D. Cervera N, et al. Among authors: garciaz s. EJHaem. 2023 Mar 17;4(2):450-453. doi: 10.1002/jha2.676. eCollection 2023 May. EJHaem. 2023. PMID: 37206278 Free PMC article.
45 results